LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Search

Cytek Biosciences Inc

Закрыт

СекторЗдравоохранение

4.17 -4.14

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

4.08

Макс.

4.36

Ключевые показатели

By Trading Economics

Доход

105K

-5.5M

Продажи

6.7M

52M

Прибыль на акцию

-0

Рентабельность продаж

-10.476

Сотрудники

692

EBITDA

6.4M

-4.2M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+38.34% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

26 февр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

69M

570M

Предыдущая цена открытия

8.31

Предыдущая цена закрытия

4.17

Новостные настроения

By Acuity

17%

83%

22 / 352 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bullish Evidence

Cytek Biosciences Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

12 февр. 2026 г., 23:57 UTC

Популярные акции

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12 февр. 2026 г., 23:35 UTC

Отчет
Главные движущие силы рынка

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12 февр. 2026 г., 23:28 UTC

Отчет

Applied Materials Profit Rises on Soaring AI Demand -- Update

12 февр. 2026 г., 21:47 UTC

Отчет

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13 февр. 2026 г., 00:00 UTC

Обсуждения рынка

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12 февр. 2026 г., 23:47 UTC

Обсуждения рынка

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12 февр. 2026 г., 23:38 UTC

Обсуждения рынка

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12 февр. 2026 г., 23:33 UTC

Отчет

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12 февр. 2026 г., 23:09 UTC

Обсуждения рынка

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12 февр. 2026 г., 22:55 UTC

Отчет
Популярные акции

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12 февр. 2026 г., 22:46 UTC

Обсуждения рынка

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12 февр. 2026 г., 22:23 UTC

Отчет

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12 февр. 2026 г., 22:15 UTC

Отчет

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12 февр. 2026 г., 22:15 UTC

Отчет

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12 февр. 2026 г., 22:15 UTC

Отчет

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12 февр. 2026 г., 22:15 UTC

Отчет

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12 февр. 2026 г., 22:00 UTC

Отчет

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 февр. 2026 г., 22:00 UTC

Отчет

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12 февр. 2026 г., 22:00 UTC

Отчет

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12 февр. 2026 г., 22:00 UTC

Отчет

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12 февр. 2026 г., 22:00 UTC

Отчет

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 февр. 2026 г., 22:00 UTC

Отчет

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12 февр. 2026 г., 21:57 UTC

Отчет

XP 4Q Rev BRL4.95B >XP

12 февр. 2026 г., 21:52 UTC

Отчет

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

12 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

12 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

12 февр. 2026 г., 21:47 UTC

Отчет

Morningstar 4Q Rev $641M >MORN

12 февр. 2026 г., 21:39 UTC

Отчет

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 февр. 2026 г., 21:38 UTC

Отчет

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Cytek Biosciences Inc Прогноз

Целевая цена

By TipRanks

38.34% рост

Прогноз на 12 месяцев

Средняя 6.17 USD  38.34%

Максимум 7.5 USD

Минимум 5 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для Cytek Biosciences Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

3 ratings

1

Покупка

2

Удержание

0

Продажа

Техническая оценка

By Trading Central

3.7 / 3.8Поддержка и Сопротивление

Краткосрочная

Weak Bullish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

22 / 352Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat